Fibrospect is based on an algorithm encompassing the concentrations of three serum markers, alpha-2 macroglobulin (A2M), hyaluronic acid (HA), and tissue inhibitor metallopeptidase protein 1 (TIMP1), to differentiate NAFLD patients with advanced fibrosis from those with milder forms of fibrosis. The gene discussed is A2M; the disease is fibrosis.